GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (NZSE:TRU) » Definitions » 3-Year Revenue Growth Rate

Truscreen Group (NZSE:TRU) 3-Year Revenue Growth Rate : 18.60% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Truscreen Group 3-Year Revenue Growth Rate?

Truscreen Group's Revenue per Share for the six months ended in Sep. 2024 was NZ$0.00.

During the past 3 years, the average Revenue per Share Growth Rate was 18.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of Truscreen Group was 44.20% per year. The lowest was -28.60% per year. And the median was -9.10% per year.

Competitive Comparison of Truscreen Group's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Truscreen Group's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Truscreen Group's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Truscreen Group's 3-Year Revenue Growth Rate falls into.


;
;

Truscreen Group 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Truscreen Group  (NZSE:TRU) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Truscreen Group 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Truscreen Group's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Truscreen Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (NZSE:TRU) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE ZBH PODD XSWX:SOON SHSE:688271 TSE:7733 PEN TSE:6869 LSE:SN. ASX:COH GMED
Traded in Other Exchanges
TRU:Australia
Address
C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Website
https://www.truscreen.com
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.